Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HCW Biologics Inc.HCWB · Entity 8172 | Chief Financial Officer | May 22, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HCW Biologics Inc.
Report date May 22, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,245 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Purchase · Acquired 14,235 · Balance 57,245 |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2031-11-22 | Direct | 18,466 |
Reported balance
After 2026-05-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-22 · Purchase · Acquired 14,235 · Balance 18,466 F1: The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 27, 2026 23:23 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock Purchase Warrant · Derivative | 14,235 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-26-025474 · ownership.xml · derivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,466 Underlying: Common Stock · 14,235 shares Expires 2031-11-22 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which purchase is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 22, 2026 Filed May 27, 2026 23:23 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 14,235 | $1.41 | $20,000.18 |
DisclosureSEC source: 0001493152-26-025474 · ownership.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,245 Read SEC document |
| May 08, 2025 Filed May 9, 2025 21:30 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 8,462 | $26.00 | $220,012.00 |
DisclosureSEC source: 0000950170-25-068281 · ownership.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,010 F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:30 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock Purchase Warrant · Derivative | 4,231 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0000950170-25-068281 · ownership.xml · derivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,231 Underlying: Common Stock · 4,231 shares Expires 2030-05-07 F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 19:19 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantCommon Stock | 760,714 | $1.40 | $1,064,999.60 |
DisclosureSEC source: 0001209191-24-003782 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,381,909 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 20:44 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option Grant (Right to Buy) · Derivative | 47,249 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-23-053344 · doc4.xml · derivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,249 shares Expires 2029-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These option shares were part of a stock option grant covering 135,000 shares of common stock. 20% of the total shares subject to the stock option grant vested on October 10, 2020; 20% of the total shares subject to the stock option grant vested on October 10, 2021; 25% of the total shares subject to the stock option grant vested on October 10, 2022; and 35% of the total shares subject to the stock option grant vested on October 10, 2023, subject to her continuous service through the applicable vesting date. The option is subject to additional vesting acceleration pursuant to her Employment Agreement. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 20:44 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 47,249 | $0.14 | $6,614.86 |
DisclosureSEC source: 0001209191-23-053344 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 621,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 22:52 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 5,000 | $2.10 | $10,490.00 |
DisclosureSEC source: 0001209191-23-049650 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 573,946 F1 · price: The range of prices for the shares of Common Stock is from $2.07 to $2.10. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 21:33 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 5,000 | $2.09 | $10,442.00 |
DisclosureSEC source: 0001209191-23-049314 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 568,946 F2 · price: The range of prices for the shares of Common Stock is from $2.07 to $2.10. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 11, 2023 Filed Sep 13, 2023 21:33 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 5,000 | $2.05 | $10,273.00 |
DisclosureSEC source: 0001209191-23-049314 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,946 F1 · price: The range of prices for the shares of Common Stock is from $2.01 to $2.09. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 21:25 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 5,000 | $2.02 | $10,111.00 |
DisclosureSEC source: 0001209191-23-048824 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 558,946 F2 · price: The range of prices for the shares of Common Stock is from $1.95 to $2.05. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 21:25 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 5,000 | $1.95 | $9,742.00 |
DisclosureSEC source: 0001209191-23-048824 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553,946 F1 · price: The range of prices for the shares of Common Stock is from $1.90 to $1.95. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 06, 2023 Filed Sep 7, 2023 20:47 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 5,000 | $1.95 | $9,749.00 |
DisclosureSEC source: 0001209191-23-048651 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 548,946 F1 · price: The range of prices for the shares of Common Stock is from $1.94 to $1.95. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 22:49 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 20,000 | $2.06 | $41,286.00 |
DisclosureSEC source: 0001209191-23-036040 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,946 F1 · price: The range of prices for the shares of Common Stock is from $1.99 to $2.18. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 23:24 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 4,696 | $2.21 | $10,387.55 |
DisclosureSEC source: 0001209191-23-035581 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,946 F2 · price: The range of prices for the shares of Common Stock is from $2.12 to $2.26. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 23:24 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 20,000 | $2.03 | $40,632.00 |
DisclosureSEC source: 0001209191-23-035581 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,250 F1 · price: The range of prices for the shares of Common Stock is from $1.90 to $2.16. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 20:46 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 19,062 | $1.82 | $34,778.62 |
DisclosureSEC source: 0001209191-23-035121 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,250 F2 · price: The range of prices for the shares of Common Stock is from $1.73 to $1.94. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:46 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 20,000 | $1.67 | $33,344.00 |
DisclosureSEC source: 0001209191-23-035121 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,188 F1 · price: The range of prices for the shares of Common Stock is from $1.625 to $1.72. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| May 26, 2023 Filed May 31, 2023 21:33 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 20,000 | $1.66 | $33,196.00 |
DisclosureSEC source: 0001209191-23-033173 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,188 F2 · price: The range of prices for the shares of Common Stock is from $1.61 to $1.81. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| May 25, 2023 Filed May 31, 2023 21:33 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 20,000 | $1.62 | $32,348.00 |
DisclosureSEC source: 0001209191-23-033173 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,188 F1 · price: The range of prices for the shares of Common Stock is from $1.57 to $1.69. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| May 24, 2023 Filed May 24, 2023 21:25 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 20,000 | $1.61 | $32,150.00 |
DisclosureSEC source: 0001209191-23-031923 · doc4.xml · nonDerivative · entry 3 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,188 F3 · price: The range of prices for the shares of Common Stock is from $1.52 to $1.70. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| May 23, 2023 Filed May 24, 2023 21:25 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 5,036 | $1.57 | $7,887.38 |
DisclosureSEC source: 0001209191-23-031923 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,188 F2 · price: The range of prices for the shares of Common Stock is from $1.57 to $1.60. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:25 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 33,450 | $1.53 | $51,044.70 |
DisclosureSEC source: 0001209191-23-031923 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,152 F1 · price: The range of prices for the shares of Common Stock is from $1.50 to $1.54. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 21:09 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option Grant (Right to Buy) · Derivative | 33,750 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-22-055548 · doc4.xml · derivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,249 Underlying: Common Stock · 33,750 shares Expires 2029-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These option shares were part of a stock option grant covering 135,000 shares of common stock. 20% of the total shares subject to the stock option grant vested on October 10, 2020; 20% of the total shares subject to the stock option grant vested on October 10, 2021; 25% of the total shares subject to the stock option grant will vest on October 10, 2022; and 35% of the total shares subject to the stock option grant will vest on October 10, 2023, subject to her continuous service through the applicable vesting date. The option is subject to additional vesting acceleration pursuant to her Employment Agreement. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 21:09 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 33,750 | $0.14 | $4,725.00 |
DisclosureSEC source: 0001209191-22-055548 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 20:27 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 15,000 | $2.58 | $38,650.50 |
DisclosureSEC source: 0001209191-22-050074 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,952 F1 · price: The range of prices for the shares of Common Stock is from $2.51 to $2.58. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 19:22 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 15,000 | $2.58 | $38,650.50 |
DisclosureSEC source: 0001209191-22-049866 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,952 F2 · price: The range of prices for the shares of Common Stock is from $2.58 to $2.63. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 19:22 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 15,000 | $2.65 | $39,763.50 |
DisclosureSEC source: 0001209191-22-049866 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,952 F1 · price: The range of prices for the shares of Common Stock is from $2.62 to $2.68. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 20:01 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 10,000 | $2.56 | $25,572.00 |
DisclosureSEC source: 0001209191-22-048239 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,952 F2 · price: The range of prices for the shares of Common Stock is from $2.56 to $2.58. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 20:01 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 7,200 | $2.55 | $18,341.28 |
DisclosureSEC source: 0001209191-22-048239 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,952 F1 · price: The range of prices for the shares of Common Stock is from $2.53 to $2.56. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 29, 2022 Filed Aug 30, 2022 21:20 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 10,000 | $2.57 | $25,662.00 |
DisclosureSEC source: 0001209191-22-048016 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,752 F2 · price: The range of prices for the shares of Common Stock is from $2.56 to $2.61. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 26, 2022 Filed Aug 30, 2022 21:20 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 10,000 | $2.54 | $25,358.00 |
DisclosureSEC source: 0001209191-22-048016 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,752 F1 · price: The range of prices for the shares of Common Stock is from $2.48 to $2.60. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 20:48 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 40,300 | $2.59 | $104,522.08 |
DisclosureSEC source: 0001209191-22-047721 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,752 F2 · price: The range of prices for the shares of Common Stock is from $2.55 to $2.75. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:48 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 50,000 | $2.50 | $125,225.00 |
DisclosureSEC source: 0001209191-22-047721 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,452 F1 · price: The range of prices for the shares of Common Stock is from $2.23 to $2.60. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 23:13 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 58,856 | $2.46 | $144,985.87 |
DisclosureSEC source: 0001209191-22-037110 · doc4.xml · nonDerivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,452 F2 · price: The range of prices for the shares of Common Stock is from $2.01 to $2.66. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 23:13 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 7,596 | $2.08 | $15,812.59 |
DisclosureSEC source: 0001209191-22-037110 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,596 F1 · price: The range of prices for the shares of Common Stock is from $1.99 to $2.2. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 17:17 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option Grant (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-21-066900 · doc4.xml · derivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,999 Underlying: Common Stock · 27,000 shares Expires 2029-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These option shares were part of a stock option grant covering 135,000 shares of common stock. 20% of the total shares subject to the stock option grant vested on October 10, 2020; 20% of the total shares subject to the stock option grant vested on October 10, 2021; 25% of the total shares subject to the stock option grant will vest on October 10, 2022; and 35% of the total shares subject to the stock option grant will vest on October 10, 2023, subject to her continuous service through the applicable vesting date. The option is subject to additional vesting acceleration pursuant to her Employment Agreement. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 17:17 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 27,000 | $0.14 | $3,780.00 |
DisclosureSEC source: 0001209191-21-066900 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 21:52 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-055531 · doc4.xml · derivative · entry 2 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-09-07 F2 · derivative.exercise_date: The option will vest as follows: 20% will vest on September 8, 2022, 20% will vest on September 8, 2023, 25% will vest on September 8, 2024 and 35% will vest on September 8, 2025. Read SEC document |
| August 29, 2021 Filed Sep 10, 2021 21:52 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001209191-21-055531 · doc4.xml · derivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2031-08-28 F1 · derivative.exercise_date: The option will vest as follows: 33% will vest on July 22, 2022, 33% will vest on July 22, 2023 and 34% will vest on July 22, 2024. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 23:50 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 10,000 | $4.40 | $43,979.00 |
DisclosureSEC source: 0001209191-21-053049 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Read SEC document |
| August 19, 2021 Filed Sep 10, 2021 21:53 UTC Amendment | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 10,000 | $4.40 | $43,979.00 |
DisclosureSEC source: 0001209191-21-055532 · doc4a.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 F1 · price: The range of prices for the shares of Common Stock is from $4.17 to $4.68. The reporting person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 23:28 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 25,000 | $8.00 | $200,000.00 |
DisclosureSEC source: 0001209191-21-048079 · doc4.xml · nonDerivative · entry 1 Byam Rebecca · CIK 0001866256 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 F1 · shares: Represents shares of Common Stock purchased in connection with the Issuer's initial public offering for consideration of $8.00 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.